Photocure is a Norwegian specialty pharmaceutical company focused on photodynamic solutions for bladder cancer detection and management. Its flagship products (Hexvix/Cysview) are used with blue-light cystoscopy to help urologists better visualize bladder tumors during examination and surgery. The company commercializes and partners these technologies in major markets, serving hospitals and specialists in urologic oncology.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q4 2024 | 141.7 | — | -4.3 | — |
| Q1 2025 | 125.3 | — | -2.4 | — |
| Q2 2025 | 135.6 | — | 4.9 | — |
| Q4 2025 | 136.7 | -3.5% | -8 | — |
| Q1 2026 | 264.6 | 111.1% | 83.4 | — |
| Q2 2026 | 142.5 | 5.1% | -0.7 | -114.6% |
All markets — KeepWinning global stock screener
Other companies on Oslo: Equinor ASA (EQNR), DNB Bank ASA (DNB), Kongsberg Gruppen ASA (KOG), Aker BP ASA (AKRBP), Telenor ASA (TEL), Norsk Hydro ASA (NHY)